A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01086696|
Recruitment Status : Terminated
First Posted : March 15, 2010
Last Update Posted : July 4, 2018
National Cancer Institute (NCI)
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Terminated|
|Actual Primary Completion Date :||August 20, 2014|
|Actual Study Completion Date :||May 11, 2016|
Hsueh WA, Kesner AL, Gangloff A, Pegram MD, Beryt M, Czernin J, Phelps ME, Silverman DH. Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET. J Nucl Med. 2006 Dec;47(12):1995-9.
Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol. 2000 Oct;27(7):661-70.